Hepatocyte mARC1 promotes fatty liver disease

Hepatocyte mARC1 promotes fatty liver disease

Background & Aims: Non-alcoholic fatty liver disease (NAFLD) has a prevalence of ∼25% worldwide, with significant public health consequences yet few effective treatments. Human genetics can help elucidate novel biology and identify targets for new therapeutics. Genetic variants in mitochondr...

Full description

Bibliographic Details
Main Authors: Lara C. Lewis, Lingyan Chen, L. Shahul Hameed, Robert R. Kitchen, Cyrielle Maroteau, Shilpa R. Nagarajan, Jenny Norlin, Charlotte E. Daly, Iwona Szczerbinska, Sara Toftegaard Hjuler, Rahul Patel, Eilidh J. Livingstone, Tom N. Durrant, Elisabeth Wondimu, Soumik BasuRay, Anandhakumar Chandran, Wan-Hung Lee, Sile Hu, Barak Gilboa, Megan E. Grandi, Enrique M. Toledo, Abdullah H.A. Erikat, Leanne Hodson, William G. Haynes, Natalie W. Pursell, Ken Coppieters, Jan Fleckner, Joanna M.M. Howson, Birgitte Andersen, Maxwell A. Ruby
Format: Article
Language:English
Published: Elsevier 2023-05-01
Series:JHEP Reports
Subjects:
Hepatic steatosis
NASH
Mendelian randomisation
Triglycerides
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555923000241

Internet

http://www.sciencedirect.com/science/article/pii/S2589555923000241

Similar Items